Navigation Links
ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
Date:6/4/2009

atements. The development and commercialization of pharmaceutical products is subject to risks and uncertainties. The Company is evaluating the complete response letter from the FDA and there can be no assurance that the Company will either amend its supplemental BLA or conduct future clinical studies with Cinryze as a treatment for acute attacks of hereditary angioedema. In the event the Company does conduct additional clinical studies, there can be no assurance that such studies will demonstrate that Cinryze successfully treats acute hereditary angioedema attacks or that the FDA will ever approve Cinryze for the acute treatment of hereditary angioedema. In addition, there can be no assurance that the FDA will not approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the market for acute treatment of HAE. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2009, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ViroPharma to Present at Two June Healthcare Conferences
2. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
3. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
4. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
5. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma to Present at Three November Healthcare Conferences
8. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
9. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
10. ViroPharma to Present at Three October Healthcare Conferences
11. ViroPharma to Present at Three September Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the ... announced an agreement with Lineagen, Inc., to ... NextStep Dx PLUS.  Lineagen, focused on ... disorders, currently offers FirstStep Dx PLUS, ... used by healthcare providers as a first-line ...
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
(Date:7/10/2014)... fractional quantum Hall effect in bilayer graphene and shown ... by an electric field. , The fractional quantum ... thin sheets are exposed to large magnetic fields, is ... individual electrons behave as a single system. However, while ... many details of this collective behavior remain not well ...
(Date:7/10/2014)... University of Illinois at Urbana-Champaign provides new insights ... spin and heat at the nanoscale, and addresses ... data storage and information processing. , "Electrons ... In a typical charge current, electrons, spin-angular-momentum is ... David Cahill, a professor of materials science and ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Detecting trace amounts of explosives with light 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3University of Illinois study advances limits for ultrafast nano-devices 2
... created equal. Information lifecycle management, a fresh concept in ... and placed them into tiers associated with different costs ... from customer orders to pictures of your last fishing ... elses data. Each piece of data doesnt have the ...
... transfer and commercialization efforts are on the rise in ... of Wisconsin to intensify its efforts at technology transfer, ... Center for Advanced Technology & Innovation (CATI) ... industry technology transfer in the Madison area. We Energies ...
... Science faculty at the University of Wisconsin-Eau Claire ... opportunities to work on research relating to materials ... university to assist local industries. , ,UW-Eau Claires ... facilitate collaboration among science faculty across disciplines, promote ...
Cached Biology Technology:Save money while your data grows 2Madison Development Corp. and CATI form tech transfer partnership 2UW-Eau Claire creates Materials Science Center 2UW-Eau Claire creates Materials Science Center 3
(Date:7/11/2014)... kidney injury related to the use of hydroxyethyl starch ... molecules, according to a report in Anesthesia & ... Society (IARS). , The "total mass of HES molecules" ... renal proximal tubule cells (PTCs), concludes the laboratory study ... Wrzburg, Austria. Other factorssuch as differences in the ...
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... by scientists at The University of Texas Medical School ... vascular smooth-muscle cells in people who suffer from hereditary ... warning in the prime of their lives. Thoracic ... dissections, is the 15th leading cause of death in ...
... appealed for more information on the worlds biodiversity to ... to understand the impact of climate change on the ... by the Biotechnology and Biological Sciences Research Council (BBSRC), ... and computer scientists at the University of Cardiff, has ...
... Researchers at Childrens Hospital of Pittsburgh of UPMC are participating ... effectiveness of oral insulin in preventing or delaying the onset ... disease. The researchers want to determine if one insulin ... type 1 diabetes in relatives of people who are found ...
Cached Biology News:Life-threatening gene defect located by UT-Houston researchers 2Life-threatening gene defect located by UT-Houston researchers 3Life-threatening gene defect located by UT-Houston researchers 4How global is the Global Biodiversity Information Facility? 2Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2
...
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
NATIVE, ENZYME PORCINE TRYPSIN...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
Biology Products: